SCHEMBL1005353

SCHEMBL1005353

CC(C)(C)[C@@H]1NC(=O)CNC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21079114 0.70
SCHEMBL1828632 0.70
SCHEMBL13428066 0.70
SCHEMBL2872608 0.70
SCHEMBL23974015 0.69 HRH3 (0.35)
SCHEMBL13644716 0.69 HRH3 (0.35)
SCHEMBL12213885 0.68
SCHEMBL13236545 0.67 LMNA (0.34)
SCHEMBL12308060 0.67 CRBN (0.32)
SCHEMBL13754182 0.66 HRH3 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724441-A1 ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF Revir Therapeutics, Inc. (US) 2026-04-15 EP disclosed
WO-2025070711-A1 AFLATOXIN PRODUCTION-INHIBITING BACTERIUM, AFLATOXIN PRODUCTION INHIBITOR PRODUCED BY AFLATOXIN PRODUCTION-INHIBITING BACTERIUM AND METHOD FOR PRODUCING SAME, AND METHOD FOR CONTROLLING AFLATOXIN CONTAMINATION USING SAID BACTERIUM OR SAID INHIBITOR 学校法人帝京大学 2025-04-03 WO disclosed
WO-2024251212-A1 ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF REVIR THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
WO-2024251211-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR MODULATING SPLICING OF MSH3 REVIR THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
US-20230331657-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS BEAM THERAPEUTICS INC. 2023-10-19 US disclosed
US-7863271-B2 2-aminobenzoxazole carboxamides as 5HT3 modulators ALBANY MOLECULAR RESEARCH, INC. (US) 2011-01-04 US disclosed
US-7485645-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2009-02-03 US disclosed
US-7485645-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2009-02-03 US disclosed
US-20080255114-A1 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS AMR TECHNOLOGY, INC. (US) 2008-10-16 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432268-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2008-10-07 US disclosed
EP-1572299-B1 17 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES SCHERING CORP (US) 2008-09-24 EP disclosed
US-20080004248-A1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES SCHERING CORPORATION 2008-01-03 US disclosed
US-20080004248-A1 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES SCHERING CORPORATION 2008-01-03 US disclosed
US-7271175-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2007-09-18 US disclosed
US-7271175-B2 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases SCHERING CORPORATION (US) 2007-09-18 US disclosed